Newsroom | Gilead - Gilead Sciences
WEBGilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline. ... Find Gilead press releases and media inquiries here.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
WEBFeb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of …
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
WEBJan 22, 2024 · EVOKE-01 is evaluating Trodelvy ® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Gilead and Assembly Biosciences Establish Partnership to Develop …
WEBOct 17, 2023 · Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit Assemblybio.com.
Gilead Sciences
WEBFor more than 35 years, we've been tackling some of the world’s greatest public health challenges. We've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and certain cancers. Now, we’ve announced our plans to enable access to our investigational medication ...
Gilead Strengthens Early Pipeline in Oncology and Inflammation …
WEBMay 9, 2023 · Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
WEBFeb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
WEBSep 12, 2024 · This could support the initial launch of the first and only twice-yearly HIV prevention choice in 2025. Gilead is executing an access strategy that prioritizes speed and enables the most efficient paths for the regulatory review and approval of lenacapavir for PrEP in regions around the world.
Full Efficacy and Safety Results for Gilead ... - Gilead Sciences
WEBJul 24, 2024 · Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at …
Kite Receives U.S. FDA Approval of Viral Vector ... - Gilead Sciences
WEBOct 3, 2022 · SANTA MONICA, Calif.-- (BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.